Dimethyltryptamine/β-carbolines
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Dimethyltryptamine/β-carbolines, also known as DMT/harmine/harmaline/THH, is a combination of dimethyltryptamine (DMT), a tryptamine serotonin receptor agonist and serotonergic psychedelic, and the β-carbolines and reversible inhibitors of MAO-A (RIMAs) harmine, harmaline, and tetrahydroharmine (THH), which is under development for potential medical use.[1][2]
 | |||
 | |||
Harmaline (left) and tetrahydroharmine (right) | |||
| Combination of | |||
|---|---|---|---|
| Dimethyltryptamine | Serotonergic psychedelic; Serotonin receptor agonist | ||
| Harmine | RIMA | ||
| Harmaline | RIMA | ||
| Tetrahydroharmine | RIMA | ||
| Clinical data | |||
| Other names | DMT/β-carboline; DMT/beta-carbolines; DMT/beta-carboline; DMT/harmine/harmaline/THH | ||
It is a form of pharmahuasca (pharmaceutical ayahuasca), in which DMT is combined with synthetically produced monoamine oxidase inhibitors (MAOIs) as opposed to a plant-derived form such as Banisteriopsis caapi as in ayahuasca.[3] The β-carbolines, acting as RIMAs, inhibit the metabolism of DMT, in turn greatly potentiating DMT and allowing it to become orally active.[4][5][6]
The combination is being developed by Psychae Therapeutics.[2] As of 2025, it is in phase 1 clinical trials.[2]